Efficacy of chemoimmunotherapy in a lung adenocarcinoma patient with mutations in the KRAS and STK11

IF 0.3 Q4 ONCOLOGY
N. Krzyżanowska, P. Krawczyk, I. Chmielewska, T. Jankowski, K. Wojas-Krawczyk, J. Milanowski
{"title":"Efficacy of chemoimmunotherapy in a lung adenocarcinoma patient with mutations in the KRAS and STK11","authors":"N. Krzyżanowska, P. Krawczyk, I. Chmielewska, T. Jankowski, K. Wojas-Krawczyk, J. Milanowski","doi":"10.5603/ocp.2023.0012","DOIUrl":null,"url":null,"abstract":"Immunotherapy is a groundbreaking treatment method when it comes to cancer, and this includes non-small-cell lung cancer (NSCLC). In NSCLC patients, immunotherapy is used in a form of immune checkpoint inhibitors (ICIs), and depending on the proportion of tumor cells with programmed death ligand 1 (PD-L1) expression on them, it can be administered either in monotherapy ( ≥ 50%) or in combination with chemotherapy (< 50%). In this article, we would like to present a case of a female patient with Kirsten Rat Sarcoma Virus ( KRAS )-mutated lung adenocarcinoma who was responding to chemoimmunotherapy for a long time despite the presence of co-mutation in the Serine/Threonine Kinase 11 ( STK11 ) gene, known to worsen immunotherapy outcomes. In this patient, another mutation was found — in the nibrin ( NBN ) gene, which is of uncertain relevance, but it presumably could be connected to a better outcome as it encodes proteins involved in DNA repair. Deficiency in DNA repair may be marked by homologous recombination deficiency (HRD), and there already exists some evidence of better immunotherapy efficacy in patients with HRD. Considering the above, further investigation and thorough genetic diagnostics in NSCLC patients are required to fully understand the background of immunotherapy","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"23 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.2023.0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immunotherapy is a groundbreaking treatment method when it comes to cancer, and this includes non-small-cell lung cancer (NSCLC). In NSCLC patients, immunotherapy is used in a form of immune checkpoint inhibitors (ICIs), and depending on the proportion of tumor cells with programmed death ligand 1 (PD-L1) expression on them, it can be administered either in monotherapy ( ≥ 50%) or in combination with chemotherapy (< 50%). In this article, we would like to present a case of a female patient with Kirsten Rat Sarcoma Virus ( KRAS )-mutated lung adenocarcinoma who was responding to chemoimmunotherapy for a long time despite the presence of co-mutation in the Serine/Threonine Kinase 11 ( STK11 ) gene, known to worsen immunotherapy outcomes. In this patient, another mutation was found — in the nibrin ( NBN ) gene, which is of uncertain relevance, but it presumably could be connected to a better outcome as it encodes proteins involved in DNA repair. Deficiency in DNA repair may be marked by homologous recombination deficiency (HRD), and there already exists some evidence of better immunotherapy efficacy in patients with HRD. Considering the above, further investigation and thorough genetic diagnostics in NSCLC patients are required to fully understand the background of immunotherapy
化疗免疫治疗在KRAS和STK11突变肺腺癌患者中的疗效
免疫疗法是一种突破性的治疗癌症的方法,包括非小细胞肺癌(NSCLC)。在非小细胞肺癌患者中,免疫治疗以免疫检查点抑制剂(ICIs)的形式使用,根据其上表达程序性死亡配体1 (PD-L1)的肿瘤细胞的比例,可以单药治疗(≥50%)或联合化疗(< 50%)。在这篇文章中,我们想要报道一例女性克尔斯滕大鼠肉瘤病毒(KRAS)突变的肺腺癌患者,尽管丝氨酸/苏氨酸激酶11 (STK11)基因存在共突变,已知会使免疫治疗结果恶化,但她对化学免疫治疗有很长时间的反应。在这个病人身上,在nibrin (NBN)基因中发现了另一个突变,这是不确定的相关性,但它可能与更好的结果有关,因为它编码了参与DNA修复的蛋白质。同源重组缺陷(homologous recombination Deficiency, HRD)可能是DNA修复缺陷的标志,已有证据表明,HRD患者的免疫治疗效果更好。综上所述,为了充分了解免疫治疗的背景,需要对NSCLC患者进行进一步的调查和彻底的遗传诊断
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.90
自引率
20.00%
发文量
46
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信